Other Health

“It’s coming, it’s happening,” he said. “And if we are the good guys in the room and we move too slowly and don’t shape what happens, then by definition it’s the bad guys who get to. And that’s a scary thought.”

BMS Australia and New Zealand General Manager Owen Smith said the ride reflects the deep connection between the company’s mission and the lived experience of patients and supporters.

Syntara (ASX:SNT) has achieved a significant regulatory milestone, announcing it has received a positive opinion from the European Medicines Agency on its application for Orphan Drug Designation for amsulostat (SNT-5505) in myelofibrosis.

Mesoblast (ASX:MSB) has appointed experienced biotechnology and pharmaceutical finance executive James M. O’Brien as its new US-based Chief Financial Officer, marking a significant step in the company’s transition toward becoming a fully integrated commercial organisation.

Argent BioPharma (ASX:RGT) has taken a significant step toward its next phase of growth, securing a new $11 million financing facility from US-based venture fund C/M Capital to complete the acquisition of AusCann Group assets and accelerate commercial development plans.

Race Oncology (ASX:RAC) has announced a significant expansion of its clinical development strategy, unveiling two new programs for its lead asset, RC220, in acute myeloid leukaemia and EGFR-mutated non-small cell lung cancer.

Noxopharm (ASX:NOX) has reached a new milestone in its development of SOF-SKN, announcing that the first dose has now been administered in Part Two of the HERACLES clinical trial.

Radiopharm Theranostics (ASX:RAD) has hit a significant milestone in its Phase 2b clinical trial evaluating RAD101, announcing that the study has now reached 50 per cent of its planned patient enrollment.

Australia’s vaccine and infectious-disease research sector has received a significant boost with the official launch of Biointelect Venturer, a new national incubator designed to accelerate local scientific breakthroughs from early discovery toward commercial reality.

The problem is that, at some point, and even before considering the global context, a funding system resembling a closed loop exhausts itself and erodes its capacity to meet its objectives. We already see that in PBS and HTA decision-making, which has become increasingly parsimonious. 

MSD has announced plans to significantly expand its presence in respiratory infectious diseases, entering into a definitive agreement to acquire San Diego–based Cidara Therapeutics in a deal valued at approximately US$9.2 billion.

Biotron (ASX:BIT) has released new data demonstrating significant progress in its Hepatitis B Virus (HBV) development program, with its lead candidate BIT-HBV001 showing potent antiviral effects across multiple laboratory and animal models.